Senior Director, Health Economics and Outcomes Research and Real-World Evidence (HEOR​/RWE

Senior Director, Health Economics and Outcomes Research and Real-World Evidence (HEOR/RWE)

Join Immatics and shape the future of cancer immunotherapy; one patient at a time!

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

Why Join Us?

• Innovative Environment:
  Help to pioneer advancements in cancer immunotherapy.
• Collaborative Culture:
  Be part of a diverse team dedicated to your professional growth.
• Global Impact:
  Contribute to therapies that make a lasting impact on patients globally.

Role Overview:

Immatics is seeking a strategic and highly collaborative Senior Director, Health Economics and Outcomes Research and Real-World Evidence (HEOR/RWE) to establish and lead the company's global HEOR and RWE capabilities. Reporting to the Vice President, Medical Affairs, this role will be responsible for generating the clinical, economic, patient-centered, and real-world evidence needed to demonstrate the value of these therapies across their development and commercialization life cycles.

The Senior Director will develop evidence strategies that address the distinct clinical and access considerations associated with innovative oncology therapies, including personalized cell therapy. The role provides an exceptional opportunity to shape the value evidence strategy for Immatics' portfolio as the company progresses late-stage development, launch readiness, and portfolio expansion.

Reports to:

Vice President, Medical Affairs

Location:

Remote

Salary Range: $260,000 - $295,000

Basic Qualifications

• Advanced scientific / medical degree required (PhD, PharmD, MD, MPH or equivalent).
• 12+ years of biotechnology or pharmaceutical industry experience, including relevant experience in evidence strategy and study execution, HEOR, RWE, market access evidence generation, epidemiology, or outcomes research.

In this Role You Will:

HEOR and RWE Strategy

• Develop and lead the global HEOR and RWE strategy for Immatics' portfolio, aligned with clinical development plans, medical strategy, regulatory priorities, market access objectives, and commercialization readiness.
• Develop integrated evidence plans and evidence-generation roadmaps that identify key research questions, evidence gaps, study priorities, data sources, timelines, and communication plans.
• Establish an HEOR and RWE framework that supports assets from early clinical development through pivotal studies, regulatory review, launch, and post-launch evidence generation.
• Anticipate evidence requirements across the United States and other priority markets, incorporating payer, reimbursement, HTA, and health-policy considerations into development plans.
• Develop annual HEOR/RWE objectives, operating plans, resource requirements, and budgets.

Evidence Generation and Research Execution

• Design and oversee HEOR and RWE studies. Develop evidence that characterizes the complete patient and healthcare-system impact of personalized cell therapy, including testing, referral, treatment-center infrastructure, manufacturing intervals, bridging therapy, hospitalization, adverse-event management, follow-up care, and long-term outcomes.
• Identify fit-for-purpose real-world data sources, including electronic health records, claims databases, registries, genomic and biomarker datasets, specialty pharmacy or treatment-center data, and linked data platforms.
• Oversee external research organizations, consultants, data vendors, academic collaborators, and other partners, including study design, contracting, budgets, timelines, deliverables, and quality.

Clinical Development and Launch Readiness

• Partner with Clinical Development, Biostatistics, Regulatory Affairs, and Medical Affairs to incorporate appropriate economic, patient-reported, healthcare-resource, and real-world endpoints into clinical development programs.
• Generate evidence addressing the unique value considerations of potentially durable oncology therapies, including limitations of conventional short-term economic assessments and uncertainty associated with extrapolating long-term benefit.
• Support payer and HTA evidence requirements, formulary submissions, value dossiers, health-economic models, scientific advice engagements, and other access-related materials.
• Collaborate with Market Access and Medical Affairs to develop evidence-based tools and resources for appropriate scientific exchange with healthcare decision-makers.

External Engagement and Scientific Communication

• Establish and maintain relationships with HEOR experts, oncology researchers, payers, HTA stakeholders, healthcare-system leaders, treatment centers, patient organizations, and real-world data partners.
• Lead external research collaborations with academic institutions, oncology networks,…